AICAR vs Survodutide
A side-by-side research comparison of AICAR and Survodutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | AICAR | Survodutide |
|---|---|---|
| Full name | AICAR (AMPK Activator / Exercise Mimetic) | Survodutide (Dual GLP-1/Glucagon Agonist) |
| Category | Weight Management | Weight Management |
| Status | Research compound | Phase 3 Clinical Trial |
| Mechanism | AICAR is converted intracellularly to ZMP, which mimics AMP and directly activates AMP-activated protein kinase (AMPK). AMPK activation shifts metabolism toward fat burning, mitochondrial biogenesis, and glucose uptake, mimicking effects of endurance exercise. | Activates GLP-1 receptors to reduce appetite while glucagon receptor activation increases hepatic fat oxidation, energy expenditure, and amino acid catabolism. |
| Molecular weight | 258.23 Da | 4,500 Da (approximate) |
| Half-life | Short | 5-7 days |
| Bioavailability | Injection (research); poor oral | High (SubQ) |
| Typical dose | Not established for humans | 0.6-6.0 mg |
| Frequency | Research only | Once weekly |
| Route | Injection (research) | Subcutaneous |
AICAR reported benefits
- AMPK activation (exercise-mimetic)
- Increased fat oxidation
- Mitochondrial biogenesis
- Improved endurance (animal models)
- Enhanced glucose uptake
Survodutide reported benefits
- Significant weight loss (up to 19%)
- Liver fat reduction
- Increased energy expenditure
- MASH resolution potential
- Improved lipid profile
Related comparisons
Research and educational reference only. Not medical advice.